AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24509688 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular septal pacing (RVSP)
Number of subjects: 38
Study 22780962 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 192
Study 22780962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 20112413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 32
Study 20112413 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy (laser therapy, steroid injections) for partial and nonresponders
Number of subjects: 32
Study 18021468 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan at 0.4 mCi/kg (for patients <= 80 kg)
Number of subjects: 170
Study 18021468 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan at 32 mCi (for patients > 80 kg)
Number of subjects: 170
Study 18021468 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (both groups)
Number of subjects: 170
Study 16241925 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (10-unit increase in diet score)
Number of subjects: 3042
Study 16241925 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 3042
Study 12435698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ARS (2.4 mg/kg) followed by intramuscular ARS (1.2 mg/kg)
Number of subjects: 28
Study 12435698 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ARS (2.4 mg/kg) followed by intravenous ARS (1.2 mg/kg)
Number of subjects: 28
Study 12435698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ARS
Number of subjects: 28
Study 10521548 — intervention group
Group type: EXPERIMENTAL
Intervention: Small hematoma (transaxial size ≤20 mm)
Number of subjects: 80
Study 10521548 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial level of consciousness
Number of subjects: 80
Study 10521548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxial size of the hematoma on CT
Number of subjects: 80
Study 7892818 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 892
Study 1955508 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week, either in the morning or in the evening for 12 months
Number of subjects: 40
Study 1955508 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week
Number of subjects: 40
Study 6791491 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition regimen adequate in amino acids and glucose
Number of subjects: 0
Study 6791491 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistarved adult patients with upper gastrointestinal tract malignancies
Number of subjects: 0
Study 6791491 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy adult controls
Number of subjects: 0
Study 30720379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal counseling sessions (4 sessions in the third trimester)
Number of subjects: 108
Study 30720379 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 108
Study 30728043 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-specific antibiotic-prescription feedback and educational outreach visit, including e-learning modules and tablet PCs with information on antibiotics.
Number of subjects: 114
Study 30728043 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 114
Study 30728043 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-spectrum antibiotics.
Number of subjects: 114
Study 30728043 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics.
Number of subjects: 114
Study 30024805 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 300
Study 30024805 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 27342514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 29
Study 27342514 — intervention group
Group type: COMPARATOR
Intervention: No hydroxyurea therapy
Number of subjects: 29
Study 25189626 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography and intervention if feasible)
Number of subjects: 200
Study 25189626 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 200
Study 22324977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographic scoring system
Number of subjects: 84
Study 22324977 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographic scoring system (excluding atelectasis)
Number of subjects: 84
Study 19149822 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day taper
Number of subjects: 516
Study 19149822 — intervention group
Group type: COMPARATOR
Intervention: 28-day taper
Number of subjects: 516
Study 17224697 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartCare - home support program for patients after coronary artery bypass graft surgery
Number of subjects: 0
Study 17224697 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐CHANGE - Internet‐based home support program designed to increase lifestyle exercise after a cardiac event
Number of subjects: 0
Study 15786530 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline
Number of subjects: 52
Study 12398954 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1587
Study 12398954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1587
Study 9857602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentalloy (superelastic nickel‐titanium alloy, 0.014 inch)
Number of subjects: 128
Study 9857602 — intervention group
Group type: COMPARATOR
Intervention: Nitinol (conventional nickel‐titanium aligning archwire, 0.014 inch)
Number of subjects: 128
Study 7783314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazobactam/Piperacillin (TAZ/PIPC)
Number of subjects: 173
Study 7783314 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (PIPC)
Number of subjects: 173
Study 2194334 — intervention group
Group type: EXPERIMENTAL
Intervention: Allomin-lactulose 2%
Number of subjects: 220
Study 2194334 — intervention group
Group type: EXPERIMENTAL
Intervention: Allomin-lactulose 4%
Number of subjects: 220
Study 389825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg t.i.d. for ten days
Number of subjects: 100
Study 389825 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 g t.i.d. for ten days
Number of subjects: 100
Study 31853594 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 33
Study 31305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium curette treatment
Number of subjects: 5
Study 31305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber reinforced plastic curette treatment
Number of subjects: 5
Study 31305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling with carbon fiber tip treatment
Number of subjects: 5
Study 31305347 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing with glycine powder
Number of subjects: 5
Study 31305347 — intervention group
Group type: COMPARATOR
Intervention: Control group without any treatment
Number of subjects: 5
Study 28533209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of allogeneic human cardiac stem cells
Number of subjects: 55
Study 28533209 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 55
Study 26179203 — intervention group
Group type: EXPERIMENTAL
Intervention: Production workers with greater barriers to cessation
Number of subjects: 713
Study 26179203 — intervention group
Group type: COMPARATOR
Intervention: Managers
Number of subjects: 713
Study 23763989 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal median CMAP amplitudes
Number of subjects: 229
Study 23763989 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal SNAP amplitude
Number of subjects: 229
Study 23763989 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal FMCV
Number of subjects: 229
Study 21542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox 6 mg/day
Number of subjects: 696
Study 21542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox 12 mg/day
Number of subjects: 696
Study 21542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox flexible-dose 12-42 mg/day
Number of subjects: 696
Study 21542016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 21542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5-4.5 mg/day
Number of subjects: 696
Study 21542016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (all doses)
Number of subjects: 696
Study 18647614 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphosemantic treatment
Number of subjects: 0
Study 18647614 — intervention group
Group type: COMPARATOR
Intervention: Morphophonological treatment
Number of subjects: 0
Study 17276965 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 43
Study 17276965 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 43
Study 12974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent reproduction
Number of subjects: 0
Study 12974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reproduction
Number of subjects: 0
Study 12974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concurrent and delayed conditions
Number of subjects: 0
Study 12974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory for a seen model
Number of subjects: 0
Study 12974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reproduction
Number of subjects: 0
Study 10900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair procedures
Number of subjects: 0
Study 10900819 — intervention group
Group type: COMPARATOR
Intervention: Unfair procedures
Number of subjects: 0
Study 10900819 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectancies
Number of subjects: 0
Study 8730113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CyA)
Number of subjects: 0
Study 8730113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8730113 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 0
Study 8730113 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (D-Pen)
Number of subjects: 0
Study 1329698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine
Number of subjects: 6
Study 1329698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporine
Number of subjects: 6
Study 1329698 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclosporine (combination therapy)
Number of subjects: 6
Study 6149592 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 0
Study 6149592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist, apomorphine (AP)
Number of subjects: 0
Study 6149592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor blockade
Number of subjects: 0
Study 31075323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet (MED/LC + 28 g walnuts/day)
Number of subjects: 278
Study 31075323 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 278
Study 28703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brush with a handle (HB)
Number of subjects: 40
Study 28703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly invented interdental cleaning device (NB)
Number of subjects: 40
Study 27045811 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily boost of 0.5 Gy
Number of subjects: 400
Study 27045811 — intervention group
Group type: COMPARATOR
Intervention: Weekly boost of 2 Gy
Number of subjects: 400
Study 26090731 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiation dose
Number of subjects: 278
Study 26090731 — intervention group
Group type: COMPARATOR
Intervention: 37% reduced radiation dose
Number of subjects: 278
Study 23361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 605
Study 23361170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 21491486 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz vibration intervention
Number of subjects: 65
Study 21491486 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 Hz vibration intervention
Number of subjects: 65
Study 21491486 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 65
Study 19418387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 19418387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 19418387 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 19418387 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnet stimulation
Number of subjects: 0
Study 17035145 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remediation aimed at moisture sources including household repairs, action plan, education, and individualized problem solving.
Number of subjects: 62
Study 17035145 — intervention group
Group type: COMPARATOR
Intervention: Control group received only home cleaning information.
Number of subjects: 62
Study 17035145 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remediation group (as treated).
Number of subjects: 62
Study 17035145 — intervention group
Group type: EXPERIMENTAL
Intervention: Home remediation group (intent to treat).
Number of subjects: 62
Study 12623166 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 30
Study 12623166 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 30
Study 10672454 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 10672454 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 9190510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus relaxation therapy (six weekly sessions of breathing and relaxation instruction)
Number of subjects: 156
Study 9190510 — intervention group
Group type: COMPARATOR
Intervention: Cardiac rehabilitation alone
Number of subjects: 156
Study 8109770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac infusion (30 mg IM premedication + 2 mg/h continuous infusion)
Number of subjects: 95
Study 8109770 — intervention group
Group type: COMPARATOR
Intervention: Control group (NaCl 0.9% IM bolus + 2 mL/h saline infusion)
Number of subjects: 95
Study 2470245 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra + LV* (high dose 200 mg/m2)
Number of subjects: 212
Study 2470245 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra + LV* (low dose 20 mg/m2)
Number of subjects: 212
Study 2470245 — intervention group
Group type: COMPARATOR
Intervention: FUra (single agent)
Number of subjects: 212
Study 2470245 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra + LV* (both doses)
Number of subjects: 212
Study 30302936 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL‐M/CLD 40/25 mg
Number of subjects: 3
Study 30302936 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL‐M/CLD 40/12.5 mg
Number of subjects: 3
Study 30302936 — intervention group
Group type: COMPARATOR
Intervention: AZL‐M 40 mg
Number of subjects: 3
Study 28818881 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 334
Study 28818881 — intervention group
Group type: COMPARATOR
Intervention: Control (GRIPHON overall population)
Number of subjects: 334
Study 26330059 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning program
Number of subjects: 161
Study 26330059 — intervention group
Group type: COMPARATOR
Intervention: peer‐reviewed articles
Number of subjects: 161
Study 24576271 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group-based rehabilitation program with monthly motivational consultation from 6 to 12 months
Number of subjects: 178
Study 24576271 — intervention group
Group type: COMPARATOR
Intervention: Oral drug treatment
Number of subjects: 178
Study 23421309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing snus
Number of subjects: 10
Study 23421309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free snus
Number of subjects: 10
Study 23421309 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution (control)
Number of subjects: 10
Study 20923610 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(B) adjuvanted split-virion H1N1 vaccine
Number of subjects: 937
Study 20923610 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted whole-virion H1N1 vaccine
Number of subjects: 937
Study 15840110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2% sirolimus for 6 weeks
Number of subjects: 24
Study 15840110 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sirolimus for an additional 6 weeks
Number of subjects: 24
Study 15840110 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 12420578 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH composite resin
Number of subjects: 4
Study 12420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 4
Study 12420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 4
Study 12420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II
Number of subjects: 4
Study 10333932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-fortified prepared meal plan
Number of subjects: 202
Study 10333932 — intervention group
Group type: COMPARATOR
Intervention: Self-selected exchange-list diet
Number of subjects: 202
Study 9183320 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) formula
Number of subjects: 24
Study 9183320 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) formula
Number of subjects: 24
Study 8245328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (recombinant tissue-type plasminogen activator, urokinase, or a combination)
Number of subjects: 348
Study 8245328 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 348
Study 3802956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interferon-alpha-2a (1.5 X 10(6) U daily for one week)
Number of subjects: 14
Study 3802956 — intervention group
Group type: COMPARATOR
Intervention: High-dose recombinant interferon-alpha-2a (18 X 10(6) U daily for one week)
Number of subjects: 14
Study 3802956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group switched to high-dose (18 X 10(6) U daily for another 7 days)
Number of subjects: 14
Study 3802956 — intervention group
Group type: COMPARATOR
Intervention: High-dose group switched to low-dose (3 X 10(6) U daily for another 7 days)
Number of subjects: 14
Study 31870450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patchouli alcohol (PA) administered intranasally
Number of subjects: 0
Study 31870450 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study 29361441 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (left tragus)
Number of subjects: 17
Study 29361441 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (earlobe)
Number of subjects: 17
Study 29361441 — intervention group
Group type: COMPARATOR
Intervention: Active vs. Control (tragus stimulation)
Number of subjects: 17
Study 26956655 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion goal (valued behavior promotion)
Number of subjects: 123
Study 26956655 — intervention group
Group type: COMPARATOR
Intervention: Unpleasant symptom promotion
Number of subjects: 123
Study 26956655 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 123
Study 26956655 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 123
Study 25059460 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong stimulation acupuncture
Number of subjects: 140
Study 25059460 — intervention group
Group type: COMPARATOR
Intervention: Weak stimulation acupuncture (sham)
Number of subjects: 140
Study 25059460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 140
Study 23187648 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment in patients with HFrEF
Number of subjects: 0
Study 20008423 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 6635
Study 20008423 — intervention group
Group type: COMPARATOR
Intervention: Palivizumab
Number of subjects: 6635
Study 18418131 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level artificial cervical disc (Bryan Cervical Disc prosthesis)
Number of subjects: 22
Study 18418131 — intervention group
Group type: COMPARATOR
Intervention: Single-level fusion with allograft and anterior cervical plate (Atlantis anterior cervical plate)
Number of subjects: 22
Study 16029268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariflex (silicone) lens
Number of subjects: 34
Study 16029268 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Fit (hydrophilic acrylic) lens
Number of subjects: 34
Study 16029268 — intervention group
Group type: EXPERIMENTAL
Intervention: AR40e (hydrophobic acrylic) lens
Number of subjects: 34
Study 11814278 — intervention group
Group type: EXPERIMENTAL
Intervention: House-dust mite avoidance measures (encasement of mattresses, pillows, and duvets; hot-water washing of bedding)
Number of subjects: 545
Study 11814278 — intervention group
Group type: COMPARATOR
Intervention: Usual care from family physician (Control)
Number of subjects: 545
Study 11814278 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of cats (in intervention families)
Number of subjects: 545
Study 11814278 — intervention group
Group type: COMPARATOR
Intervention: Control group (families who did not remove cats)
Number of subjects: 545
Study 10523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg/day
Number of subjects: 201
Study 10523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg/day
Number of subjects: 201